secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2026-07-29T10:10:24+00:00
Accession:  0000875045-26-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q2 revenue $2.7B (+3% YoY); GAAP EPS $0.66, Non-GAAP $3.60; Growth Portfolio up 24% to $1.06B
--------------------------------------------------------------------------------

- Total revenue $2.7B (+3% YoY); GAAP diluted EPS $0.66 (down 85%), Non-GAAP diluted EPS $3.60 (down 34%).
- Growth Portfolio revenue $1.06B (+24% YoY); SPINRAZA $402M (+2%), LEQEMBI in-market $184M (+15%), SKYCLARYS $168M (+29%).
- Apellis acquisition closed May 14; SYFOVRE $162M (Biogen $97M), EMPAVELI $46M (Biogen $30M); $0.85 dilution to Non-GAAP EPS in 2026, accretive 2027.
- Pipeline: litifilimab SLE data by end-2026; diranersen proof-of-concept in Alzheimer's; pending RayThera acquisition.
- Full year 2026 guidance updated reflecting stronger underlying business outlook adjusted for transactions and milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/0000875045-26-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/biib-20260729.htm
  HTML page:      https://secwatch.observer/filing/0000875045-26-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer